Genoimmune Therapeutics

Genoimmune Therapeutics is a China-based immuno-oncology biotech affiliated with BGI that develops personalized and engineered immune therapies for cancer. The company focuses on neoantigen-directed T-cell therapies, CAR-T programs, dendritic cell vaccines, and mRNA-based cancer vaccines for solid tumors and hematologic malignancies. Its best-documented clinical asset is Neo-T, an autologous neoantigen-targeting T-cell product that has entered Phase 1 testing in advanced solid tumors, including combination studies with PD-1 antibodies. Genoimmune also appears to position itself as a platform company, combining genomics, bioinformatics, AI-enabled neoantigen prediction, and cell manufacturing capabilities to generate individualized immunotherapies. Public sources conflict on its current operating status, but recent pipeline and affiliated institute materials indicate ongoing development activity in China.